dkbmed Logo

Sophie: A Case Study in CF Management

Pulmonary Disease
A Case Study in CF Management
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
October 23, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This activity is intended for pulmonologists; pediatric pulmonologists; pediatricians; respiratory therapists; and others involved in the care of patients with cystic fibrosis.

Relevant Terms:

Cystic fibrosis; pulmonary exacerbations; inhaled antibiotic therapy

Patrick Flume, MD

Patrick Flume, MD
Professor of Medicine and Pediatrics
The Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
Charleston, South Carolina

Patrick Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina and has been part of the MUSC program since 1993.  He serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis and oversees a rapidly growing Cystic Fibrosis Center, including the largest adult CF program in South Carolina. 
He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, the European CF Society’s Best Practices committee, and as founding co-chair of the CF Foundation’s Pulmonary Practice Guidelines Committee.  He is the Deputy Editor for the Journal of Cystic Fibrosis.
His also leads a very busy clinical research program for CF. Many of these studies are related to new drug and therapy development for patients with CF, but he also has an interest in determining optimal management of pulmonary exacerbations and is the co-PI in the STOP trials, aimed at identifying optimal treatments for exacerbations.    

Michael S. Schechter, MD, MPH

Michael S. Schechter, MD, MPH
Professor and Chief, Division of Pulmonary Medicine
Department of Pediatrics
Virginia Commonwealth University
Children's Hospital of Richmond at VCU
Richmond, Virginia

Dr. Schechter is professor and chief of the Division of Pulmonary Medicine at the Children's Hospital of Richmond at Virginia Commonwealth University and Director of the VCU Cystic Fibrosis Center.

Dr. Schechter's research has focused on environmental and sociodemographic influences as well as the impact of treatment variations on outcomes in Cystic Fibrosis, and his investigative work has primarily involved secondary database analyses.  He has also worked with the CF Foundation on fostering methods to improve the quality of care and outcomes for children with CF, and has participated in projects to improve the care of children with other chronic conditions such as Spina Bifida, Inflammatory Bowel Disease, Sickle Cell Disease, and Asthma.  

Dr. Schechter has served on numerous committees of the Cystic Fibrosis Foundation, American Thoracic Society, and American Academy of Pediatrics, and is past chair of the AAP Section of Pediatric Pulmonology and Sleep.
1. Evaluate currently available data on Pseudomonas aeruginosa therapies.
2. Discuss treatment options when first-line (chronic) inhaled antibiotics fail.
3. Apply current information to design effective long-term alternating inhaled antibiotic therapy schedules.

Accreditation Statement 
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Target Audience
This activity is intended for pulmonologists, pedi­atric pulmo­nologists, pediatricians, respiratory thera­pists, and others involved in the care of patients with cystic fibrosis.
Educational Support 
This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Patrick Flume, MD: Consulting fees from Bayer Heathcare AG, Corbus Pharmaceuticals, Eloxx Pharmaceuticals, Horizon Pharma, Insmed, McKesson, Novartis, Proteostasis Therapeutics, Vertex Pharmaceuticals, Inc. Fees related to commercial interests: Bayer Heathcare AG, Corbus Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, Galapagos, Insmed, National Institutes of Health, Novartis, Novoteris, Proteostasis Therapeutics, Sound Pharmaceuticals, Inc., and Vertex Pharmaceuticals, Inc.  
Michael S. Schechter, MD, MPH: Consulting fees from Vertex Pharmaceuticals, Inc. and commercial interest from Astra-Zeneca.
Planners and Managers
The PIM planners and managers have nothing to disclose.
The following DKB planners and managers Stan Pogroszewski, and Lisa Alvarado hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Jointly provided by Postgraduate Institute for Medicine and DKBmed, LLC.
Estimated time to complete activity: 0.5 hours.
Method of Participating and Request for Credit
There are no fees for participation in this CME activity. To receive credit, participants must 1) read the learning objectives and disclosure statements, 2) complete the educational activity and 3) complete the post-test and activity evaluation.
Presented by PIM in collaboration with DKBmed
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.